Related Experiment Videos
FDG accumulation and tumor biology
E K Pauwels1, M J Ribeiro, J H Stoot
1Leiden University Medical Centre, Department of Radiology, The Netherlands.
Nuclear Medicine and Biology
|June 25, 1998
Summary
Fluorine-18-deoxyglucose (FDG) tumor uptake relies on increased glycolysis, glucose transporters, and hexokinase activity. However, FDG uptake is not specific to tumors, necessitating careful patient selection for clinical use.
Area of Science:
- Oncology
- Nuclear Medicine
- Biochemistry
Background:
- Tumoral uptake of fluorine-18-deoxyglucose (FDG) is a key PET imaging principle.
- Enhanced glycolysis in cancer cells drives increased FDG accumulation.
- FDG uptake is influenced by glucose transporters and hexokinase activity.
Purpose of the Study:
- To elucidate the mechanisms underlying enhanced FDG uptake in tumors.
- To discuss the implications of these mechanisms for clinical PET imaging.
Main Methods:
- Review of established biochemical and cellular processes related to glucose metabolism.
- Analysis of the role of glucose transporter proteins and hexokinase.
- Consideration of the impact of tumor microenvironment factors like hypoxia.
Main Results:
- FDG is phosphorylated and trapped intracellularly, a process facilitated by glucose transporters.
- Hexokinase activity, particularly when bound to mitochondria, enhances intracellular FDG trapping.
- Tumor-associated hypoxia can further increase anaerobic glycolysis and FDG uptake.
- FDG uptake is observed in all metabolically active cells, not exclusively tumors.
Conclusions:
- Tumoral FDG uptake is multifactorial, involving enhanced glycolysis, glucose transporters, hexokinase, and hypoxia.
- The relatively nonspecific nature of FDG uptake requires careful patient selection for accurate diagnostic interpretation.
- FDG-PET imaging remains valuable but necessitates consideration of its inherent limitations.